Alnylam Pharmaceuticals has received Fast Track designation from the FDA for patisiran (ALN-TTR02) for the treatment of transthyretin (TTR)-familial amyloid polyneuropathy (FAP). Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Alnylam recently announced positive Phase II data, which showed that multiple doses of patisiran l...